NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: NURECA · data 2026-10-30
Nureca Ltd.
In plain words
Price: 21.9% below its 52-week high of ₹376.
Delivery: 60.0% of traded shares were kept for delivery over the last 10 sessions, against 57.1% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Jun 2026 (+279.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹174 cr |
| Net profit (last 12 months) | ₹5 cr |
| Sales growth, 3 years (yearly) | 9.7% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q1 FY27)
NURECA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹40.34 crore, up 18% YoY and up 13.9% QoQ.
Net profit was ₹3.07 crore, up 279% YoY and a turn to profit from a loss last quarter.
Operating margin was 8.5% (1.6% a year ago).
EPS was ₹3.21, up 296.3% YoY and positive against a negative EPS last quarter.
NURECA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹40.34 करोड़; पिछले साल की तुलना में 18% की बढ़त, पिछली तिमाही की तुलना में 13.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹3.07 करोड़; पिछले साल की तुलना में 279% की बढ़त, पिछली तिमाही के घाटे से मुनाफ़े में आया।
ऑपरेटिंग मार्जिन: 8.5% (एक साल पहले 1.6%)।
EPS: ₹3.21; पिछले साल की तुलना में 296.3% की बढ़त, पिछली तिमाही के ऋणात्मक EPS से धनात्मक हुआ।
NURECAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹40.34 કરોડ; ગયા વર્ષની સરખામણીએ 18% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13.9% વધારો.
ચોખ્ખો નફો: ₹3.07 કરોડ; ગયા વર્ષની સરખામણીએ 279% વધારો, ગયા ક્વાર્ટરની ખોટમાંથી નફામાં આવી.
ઓપરેટિંગ માર્જિન: 8.5% (એક વર્ષ પહેલાં 1.6%).
EPS: ₹3.21; ગયા વર્ષની સરખામણીએ 296.3% વધારો, ગયા ક્વાર્ટરના નકારાત્મક EPSથી હકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 24 Sept 26Insider SAST disclosure: Saurabh Goyal +1 acquired 1,96,993 shares +4.7% next session
- 21 Jul 26Results Q1 FY27 results: profit +279.0% YoY +10.2% next session
- 29 May 26Results Q4 FY26 results: turned to loss vs a year ago -11.8% next session
- 17 Jan 26Results Q3 FY26 results: turned to profit vs a year ago +4.8% next session
- 5 Jan 26Results Q2 FY26 results: turned to profit vs a year ago -2.0% next session
- 15 Jul 25Results Q1 FY26 results: profit −51.2% YoY -9.5% next session
- 7 May 25Results Q4 FY25 results: turned to profit vs a year ago +4.0% next session
- 24 Jan 25Results Q3 FY25 results: turned to loss vs a year ago -9.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹40 cr | ₹3 cr | +279.0% | 8.5% | 3.21 |
| Mar 2026 | ₹35 cr | ₹-6 cr | -346.6% | -16.3% | -6.45 |
| Dec 2025 | ₹40 cr | ₹4 cr | — | 8.2% | 3.91 |
| Sept 2025 | ₹38 cr | ₹4 cr | — | 8.7% | 3.63 |
Common questions
What was Nureca Ltd.'s latest quarterly profit?
Nureca Ltd. reported a net profit of ₹3 cr for the quarter ended Jun 2026 (+279.0% on the same quarter a year earlier), on revenue of ₹40 cr.
Is Nureca Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Nureca Ltd.'s P/E ratio?
About 61.1, based on the last 12 months' earnings and a price of ₹293.8 (data 2026-10-30).
What is the 52-week high and low of Nureca Ltd.?
The 52-week high is ₹376 and the 52-week low is ₹204.
Similar companies
Q-Line Biotech Limited (QLINE) · MIC Electronics Limited (MICEL) · Osel Devices Limited (OSELDEVICE) · Yash Optics and Lens Limited (YASHOPTICS) · Avience Biomedicals Limited (AVIENCE)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NURECA in NSE Scanner →